Advantage Austria Show navigation

Austrian biotech excellence in Cambridge

- © ADVANTAGE AUSTRIA

© ADVANTAGE AUSTRIA

12. July 2008

Austrian antibody engineering company F-Star opens research site at the Babraham Research Campus

f-star , an antibody engineering company developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology, has set up a research facility in Cambridge in addition to its headquarters in Vienna. The facility is located at the Babraham Research Campus , home to a number of biotech companies and close to the Medical Research Council's Laboratory of Molecular Biiology (LMB) , the major center for antibody engineering in Europe.

f-star was founded in 2006 and employs more than 20 highly qualified people at its headoffice in Vienna. In its advisory board the company is supported by pioneers in the field of monoclonal antibodies - Sir Ravinder Maini (Imperial College London), Prof Anthony Rees (MIP Technologies AB) and Sir Gregory Winter (MRC Laboratory of Molecular Biology). f-star enjoys the strong financial support from a world-class group of life science investors including Aescap Venture, Atlas Venture, Novo A/S and TVM Capital.

f-star is one of 140 life sciences companies based in Vienna which employ a  total of about 10,000 people. There are a further 3,800 researchers also active in the field at five universities and a wide variety of non-university research organisations. Vienna has a long tradition of excellent scientific and medical research: Semmelweis, Billroth and Landsteiner are all part of this proud history. The traditions of the Second Vienna Medical School are expressed today in a focus on medical biotechnology centring on vaccinations, antiinfectives, immunology and oncology.
 
Download a directory of Austrian biotech and life sciences companies here Austria Export Biotech and more [pdf, 1,021.8kb].

print
©©ADVANTAGE AUSTRIA